Loading…
Antiphospholipid Antibodies in Patients with Coronary Artery Disease
: Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute coronary syndromes (ACS) to determine if aPL were associated with the presence and severity of CAD, adverse outcomes, and...
Saved in:
Published in: | Annals of the New York Academy of Sciences 2007-06, Vol.1108 (1), p.466-474 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c1289-6df604c6f0cbeec578e7ee4dea445d4559380b547478b1016e56f8c69a9cd9723 |
---|---|
cites | |
container_end_page | 474 |
container_issue | 1 |
container_start_page | 466 |
container_title | Annals of the New York Academy of Sciences |
container_volume | 1108 |
creator | GRECO, TOM P. CONTI-KELLY, ANN MARIE MATSUURA, EIJI GRECO Jr, TOM DIER, KEN J. SVANAS, GREGORY DOYLE, ROBIN LOPEZ, LUIS R. |
description | : Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute coronary syndromes (ACS) to determine if aPL were associated with the presence and severity of CAD, adverse outcomes, and other coronary risk factors. Patients with chest pain/ACS were evaluated for aPL prior to diagnostic and therapeutic investigations. Coronary angiograms were graded according to the severity of disease. Risk factors, including family histories, were assessed and patients were followed for adverse outcomes. To date, 232 patients (116 M, 116 F, mean age 63 years) with a mean follow‐up of 9 months were studied. Thirty‐seven percent (86/232) were positive for one or more aPL. More women, 49/86 (57%), were aPL positive versus men, 37/86 (43%). The presence of aPL appeared associated with both presence and severity of CAD (P= 0.176 women; P= 0.163 men). In patients undergoing procedures (angioplasty, stent, bypass), aPL was significantly associated with both an increase in adverse cardiac outcomes (P= 0.045) and extracardiac thrombotic events (P= 0.033). Anti‐β2 glycoprotein‐1 (aβ2GP1) was the most frequent aPL, occurring in 68.5% of aPL‐positive patients with CAD. Anticardiolipin antibody (aCL) occurred in only 7.4%. IgM isotypes were the most frequent for all categories of aPL (range 55–90%). Family history of antiphospholipid syndrome (APS)‐related events was more significant in aPL‐positive than aPL‐negative individuals (P= 0.027). |
doi_str_mv | 10.1196/annals.1422.049 |
format | article |
fullrecord | <record><control><sourceid>wiley_istex</sourceid><recordid>TN_cdi_wiley_primary_10_1196_annals_1422_049_NYAS49</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NYAS49</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1289-6df604c6f0cbeec578e7ee4dea445d4559380b547478b1016e56f8c69a9cd9723</originalsourceid><addsrcrecordid>eNo9kF1LwzAUhoMoOKfX3vYPtCbNSdJclk6nMKbgdHgV0vaURWc7msLcvzel4sXhhQPvBw8ht4wmjGl5Z9vW7n3CIE0TCvqMzJgCHUvJ03Myo1SpONMpvyRX3n9SytIM1Iws8nZwh13nw-3dwdXR-Ci72qGPXBu92MFhO_jo6IZdVHR919r-FOX9gEEWzqP1eE0umtCNN386J28P95viMV49L5-KfBVXoS1MqRtJoZINrUrESqgMFSLUaAFEDUJontFSgAKVlYwyiUI2WSW11VWtVcrnhE-5R7fHkzn07juMMYyakYCZCJiRgAkEzPojfwUdXPHkcn7An3-X7b-MVFwJs10vzbugTMB6azb8F5uqYak</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Antiphospholipid Antibodies in Patients with Coronary Artery Disease</title><source>Wiley</source><creator>GRECO, TOM P. ; CONTI-KELLY, ANN MARIE ; MATSUURA, EIJI ; GRECO Jr, TOM ; DIER, KEN J. ; SVANAS, GREGORY ; DOYLE, ROBIN ; LOPEZ, LUIS R.</creator><creatorcontrib>GRECO, TOM P. ; CONTI-KELLY, ANN MARIE ; MATSUURA, EIJI ; GRECO Jr, TOM ; DIER, KEN J. ; SVANAS, GREGORY ; DOYLE, ROBIN ; LOPEZ, LUIS R.</creatorcontrib><description>: Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute coronary syndromes (ACS) to determine if aPL were associated with the presence and severity of CAD, adverse outcomes, and other coronary risk factors. Patients with chest pain/ACS were evaluated for aPL prior to diagnostic and therapeutic investigations. Coronary angiograms were graded according to the severity of disease. Risk factors, including family histories, were assessed and patients were followed for adverse outcomes. To date, 232 patients (116 M, 116 F, mean age 63 years) with a mean follow‐up of 9 months were studied. Thirty‐seven percent (86/232) were positive for one or more aPL. More women, 49/86 (57%), were aPL positive versus men, 37/86 (43%). The presence of aPL appeared associated with both presence and severity of CAD (P= 0.176 women; P= 0.163 men). In patients undergoing procedures (angioplasty, stent, bypass), aPL was significantly associated with both an increase in adverse cardiac outcomes (P= 0.045) and extracardiac thrombotic events (P= 0.033). Anti‐β2 glycoprotein‐1 (aβ2GP1) was the most frequent aPL, occurring in 68.5% of aPL‐positive patients with CAD. Anticardiolipin antibody (aCL) occurred in only 7.4%. IgM isotypes were the most frequent for all categories of aPL (range 55–90%). Family history of antiphospholipid syndrome (APS)‐related events was more significant in aPL‐positive than aPL‐negative individuals (P= 0.027).</description><identifier>ISSN: 0077-8923</identifier><identifier>EISSN: 1749-6632</identifier><identifier>DOI: 10.1196/annals.1422.049</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>acute coronary syndromes ; antiphospholipid syndrome ; cardiac risk ; β2GP1 antibodies</subject><ispartof>Annals of the New York Academy of Sciences, 2007-06, Vol.1108 (1), p.466-474</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1289-6df604c6f0cbeec578e7ee4dea445d4559380b547478b1016e56f8c69a9cd9723</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>GRECO, TOM P.</creatorcontrib><creatorcontrib>CONTI-KELLY, ANN MARIE</creatorcontrib><creatorcontrib>MATSUURA, EIJI</creatorcontrib><creatorcontrib>GRECO Jr, TOM</creatorcontrib><creatorcontrib>DIER, KEN J.</creatorcontrib><creatorcontrib>SVANAS, GREGORY</creatorcontrib><creatorcontrib>DOYLE, ROBIN</creatorcontrib><creatorcontrib>LOPEZ, LUIS R.</creatorcontrib><title>Antiphospholipid Antibodies in Patients with Coronary Artery Disease</title><title>Annals of the New York Academy of Sciences</title><description>: Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute coronary syndromes (ACS) to determine if aPL were associated with the presence and severity of CAD, adverse outcomes, and other coronary risk factors. Patients with chest pain/ACS were evaluated for aPL prior to diagnostic and therapeutic investigations. Coronary angiograms were graded according to the severity of disease. Risk factors, including family histories, were assessed and patients were followed for adverse outcomes. To date, 232 patients (116 M, 116 F, mean age 63 years) with a mean follow‐up of 9 months were studied. Thirty‐seven percent (86/232) were positive for one or more aPL. More women, 49/86 (57%), were aPL positive versus men, 37/86 (43%). The presence of aPL appeared associated with both presence and severity of CAD (P= 0.176 women; P= 0.163 men). In patients undergoing procedures (angioplasty, stent, bypass), aPL was significantly associated with both an increase in adverse cardiac outcomes (P= 0.045) and extracardiac thrombotic events (P= 0.033). Anti‐β2 glycoprotein‐1 (aβ2GP1) was the most frequent aPL, occurring in 68.5% of aPL‐positive patients with CAD. Anticardiolipin antibody (aCL) occurred in only 7.4%. IgM isotypes were the most frequent for all categories of aPL (range 55–90%). Family history of antiphospholipid syndrome (APS)‐related events was more significant in aPL‐positive than aPL‐negative individuals (P= 0.027).</description><subject>acute coronary syndromes</subject><subject>antiphospholipid syndrome</subject><subject>cardiac risk</subject><subject>β2GP1 antibodies</subject><issn>0077-8923</issn><issn>1749-6632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNo9kF1LwzAUhoMoOKfX3vYPtCbNSdJclk6nMKbgdHgV0vaURWc7msLcvzel4sXhhQPvBw8ht4wmjGl5Z9vW7n3CIE0TCvqMzJgCHUvJ03Myo1SpONMpvyRX3n9SytIM1Iws8nZwh13nw-3dwdXR-Ci72qGPXBu92MFhO_jo6IZdVHR919r-FOX9gEEWzqP1eE0umtCNN386J28P95viMV49L5-KfBVXoS1MqRtJoZINrUrESqgMFSLUaAFEDUJontFSgAKVlYwyiUI2WSW11VWtVcrnhE-5R7fHkzn07juMMYyakYCZCJiRgAkEzPojfwUdXPHkcn7An3-X7b-MVFwJs10vzbugTMB6azb8F5uqYak</recordid><startdate>200706</startdate><enddate>200706</enddate><creator>GRECO, TOM P.</creator><creator>CONTI-KELLY, ANN MARIE</creator><creator>MATSUURA, EIJI</creator><creator>GRECO Jr, TOM</creator><creator>DIER, KEN J.</creator><creator>SVANAS, GREGORY</creator><creator>DOYLE, ROBIN</creator><creator>LOPEZ, LUIS R.</creator><general>Blackwell Publishing Inc</general><scope>BSCLL</scope></search><sort><creationdate>200706</creationdate><title>Antiphospholipid Antibodies in Patients with Coronary Artery Disease</title><author>GRECO, TOM P. ; CONTI-KELLY, ANN MARIE ; MATSUURA, EIJI ; GRECO Jr, TOM ; DIER, KEN J. ; SVANAS, GREGORY ; DOYLE, ROBIN ; LOPEZ, LUIS R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1289-6df604c6f0cbeec578e7ee4dea445d4559380b547478b1016e56f8c69a9cd9723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>acute coronary syndromes</topic><topic>antiphospholipid syndrome</topic><topic>cardiac risk</topic><topic>β2GP1 antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GRECO, TOM P.</creatorcontrib><creatorcontrib>CONTI-KELLY, ANN MARIE</creatorcontrib><creatorcontrib>MATSUURA, EIJI</creatorcontrib><creatorcontrib>GRECO Jr, TOM</creatorcontrib><creatorcontrib>DIER, KEN J.</creatorcontrib><creatorcontrib>SVANAS, GREGORY</creatorcontrib><creatorcontrib>DOYLE, ROBIN</creatorcontrib><creatorcontrib>LOPEZ, LUIS R.</creatorcontrib><collection>Istex</collection><jtitle>Annals of the New York Academy of Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GRECO, TOM P.</au><au>CONTI-KELLY, ANN MARIE</au><au>MATSUURA, EIJI</au><au>GRECO Jr, TOM</au><au>DIER, KEN J.</au><au>SVANAS, GREGORY</au><au>DOYLE, ROBIN</au><au>LOPEZ, LUIS R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiphospholipid Antibodies in Patients with Coronary Artery Disease</atitle><jtitle>Annals of the New York Academy of Sciences</jtitle><date>2007-06</date><risdate>2007</risdate><volume>1108</volume><issue>1</issue><spage>466</spage><epage>474</epage><pages>466-474</pages><issn>0077-8923</issn><eissn>1749-6632</eissn><abstract>: Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute coronary syndromes (ACS) to determine if aPL were associated with the presence and severity of CAD, adverse outcomes, and other coronary risk factors. Patients with chest pain/ACS were evaluated for aPL prior to diagnostic and therapeutic investigations. Coronary angiograms were graded according to the severity of disease. Risk factors, including family histories, were assessed and patients were followed for adverse outcomes. To date, 232 patients (116 M, 116 F, mean age 63 years) with a mean follow‐up of 9 months were studied. Thirty‐seven percent (86/232) were positive for one or more aPL. More women, 49/86 (57%), were aPL positive versus men, 37/86 (43%). The presence of aPL appeared associated with both presence and severity of CAD (P= 0.176 women; P= 0.163 men). In patients undergoing procedures (angioplasty, stent, bypass), aPL was significantly associated with both an increase in adverse cardiac outcomes (P= 0.045) and extracardiac thrombotic events (P= 0.033). Anti‐β2 glycoprotein‐1 (aβ2GP1) was the most frequent aPL, occurring in 68.5% of aPL‐positive patients with CAD. Anticardiolipin antibody (aCL) occurred in only 7.4%. IgM isotypes were the most frequent for all categories of aPL (range 55–90%). Family history of antiphospholipid syndrome (APS)‐related events was more significant in aPL‐positive than aPL‐negative individuals (P= 0.027).</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><doi>10.1196/annals.1422.049</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0077-8923 |
ispartof | Annals of the New York Academy of Sciences, 2007-06, Vol.1108 (1), p.466-474 |
issn | 0077-8923 1749-6632 |
language | eng |
recordid | cdi_wiley_primary_10_1196_annals_1422_049_NYAS49 |
source | Wiley |
subjects | acute coronary syndromes antiphospholipid syndrome cardiac risk β2GP1 antibodies |
title | Antiphospholipid Antibodies in Patients with Coronary Artery Disease |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A00%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_istex&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiphospholipid%20Antibodies%20in%20Patients%20with%20Coronary%20Artery%20Disease&rft.jtitle=Annals%20of%20the%20New%20York%20Academy%20of%20Sciences&rft.au=GRECO,%20TOM%20P.&rft.date=2007-06&rft.volume=1108&rft.issue=1&rft.spage=466&rft.epage=474&rft.pages=466-474&rft.issn=0077-8923&rft.eissn=1749-6632&rft_id=info:doi/10.1196/annals.1422.049&rft_dat=%3Cwiley_istex%3ENYAS49%3C/wiley_istex%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1289-6df604c6f0cbeec578e7ee4dea445d4559380b547478b1016e56f8c69a9cd9723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |